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presumed to favor spontaneous conversion of the pro-
tein to the PrPSc state without the necessity for contact
with an exogenous infectious agent (Cohen et al., 1994).
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To understand familial prion diseases at the cellularIndianapolis, Indiana 46202
and molecular level, it is necessary to develop experi-
mental systems whereby PrPSc can be generated de
novo from PrP molecules that carry pathogenic muta-Summary
tions. In previous work, we have accomplished this
transformation in a cell culture system by constructingFamilial prion diseases are caused by mutations in
stably transfected lines of CHO cells that express mutantthe gene encoding the prion protein (PrP). We have
mouse PrP (moPrP) molecules whose human homologsproduced transgenic mice that express the mouse ho-
are associated with each of the three familial prion dis-molog of a mutant human PrP containing a nine octa-
eases of humans (Lehmann and Harris, 1995, 1996a,peptide insertion associated with prion dementia.
1996b, 1997; Daude et al., 1997; Lehmann et al., 1997).These mice exhibit a slowly progressive neurological
We found that these mutant proteins acquired severaldisorder characterized clinically by ataxia and neuro-
biochemical attributes reminiscent of PrPSc, includingpathologically by cerebellar atrophy and granule cell
detergent insolubility, protease resistance, resistanceloss, gliosis, and PrP deposition that is most prominent
to release from cell membranes by phospholipase, andin the cerebellum and hippocampus. Mutant PrP mole-
long metabolic half-life. These cells have allowed us tocules expressed in the brains of these mice are resis-
address a number of key issues in prion biology, includ-tant to digestion by low concentrations of proteinase
ing the identification of biochemical intermediates in theK and display several other biochemical properties
generation of PrPSc, cellular trafficking and the compart-reminiscent of PrPSc, the pathogenic isoform of PrP.
mentalization of PrPSc, and the membrane associationThese results establish a new transgenic animal model
of PrPSc.of an inherited human prion disorder.
There are a number of important questions about fa-
milial prion diseases that cannot be answered with a
Introduction cell culture system and that require the use of an animal
model. We report here the construction of mice that
Prion diseases are fatal neurodegenerative disorders express a moPrP transgene containing a nine octapep-
that are characterized clinically by dementia and motor tide insertional mutation. The human homolog of this
dysfunction and neuropathologically by spongiform de- mutation, which is the largest insertion thus far de-
generation and amyloid formation in the brain. These scribed in the PrP gene, has been found in two patients
diseases are attributable to the conformational conver- (one British and one German) who were afflicted with
sion of a normal, cell surface glycoprotein (PrPC) into an illness characterized by progressive dementia and
a pathogenic isoform (PrPSc) that is infectious in the ataxia, and in the one autopsied case by the presence
apparent absence of nucleic acid (Prusiner et al., 1998). of PrP-containing amyloid plaques in the cerebellum
This molecular alteration involves the transformation of and basal ganglia (Owen et al., 1992; Duchen et al.,
a-helical or unstructured regions of the polypeptide 1993; Krasemann et al., 1995). We find that transgenic
chain into b-sheets (Donne et al., 1997; Harrison et al., mice expressing the mutant moPrP develop a neurologi-
1997; Riek et al., 1997). cal illness that features ataxia, neuropathological abnor-
Prion diseases can have an infectious or genetic etiol- malities, and the accumulation of PrP forms in the brain
ogy or can arise sporadically. We have been interested that display several biochemical properties reminiscent
in familial prion diseases, which include 10% of the of PrPSc.
cases of Creutzfeldt-Jakob disease (CJD) and all cases
of Gerstmann-StraÈ ussler syndrome (GSS) and fatal fa-
Resultsmilial insomnia (FFI) (Prusiner and Hsiao, 1994; Parchi
and Gambetti, 1995; Young et al., 1999). These diseases
Generation of Transgenic Mice and Characterizationare all linked to dominantly inherited, germline mutations
of PrP Expressionin the PrP gene on chromosome 20. The mutations are
We have generated transgenic mice that express a
mouse homolog of the nine octapeptide PrP insertion
described in human beings; we will refer to the resulting³ To whom correspondence should be addressed: (e-mail: dharris@
cellbio.wustl.edu). mutant PrP molecule as PG14, since it contains a total
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Tg(PG14) Mice Develop Neurological SymptomsTable 1. Characteristics of Transgenic Mouse Lines Expressing
A slowly progressive neurological disorder was ob-Wild-Type and PG14 PrP
served in Tg(PG14) mice that had the highest expression
Transgene Tg PrP
levels of the mutant protein. Included in this group areTransgene Line Copy Numbera Proteinb
the nonbreeding A1 founder that expressed PG14 PrP
PG14 PrP Tg(PG14-A1) 28 4.0 at four times the endogenous PrP level and mice of
(3F4-tagged) Tg(PG14-A2) 5 1.0 the A2 and A3 lines, which express one times the en-
Tg(PG14-A3) 33 1.0
dogenous level. The primary symptoms of the disorder,Tg(PG14-B) 2 0.15
which are observable throughout the course of illness,Tg(PG14-C) 4 0.15
include ataxia (lack of coordination), kyphosis (hunch-
Wild-type PrP Tg(WT-D) 92 NDc
back posture), and clasping of the hind limbs when(3F4-tagged) Tg(WT-E1) 9 1.8
the mice are held by their tails (normal mice splay theirTg(WT-E2) 1 0.25
hind limbs apart) (Figures 1A±1D). As the disease pro-Tg(WT-E3) 59 3.6
Tg(WT-E4) 15 3.0 gresses, affected mice show hypokinesia (decreased
spontaneous movement), a waddling gait, difficultya Determined by quantitative Southern blotting of tail DNA. Data are
righting from a supine position, weight loss, and a ruffledfor mice that are hemizygous for the transgene array.
b Determined relative to endogenous hamster PrP by quantitative appearance of their coats that may be attributable to
Western blotting of brain homogenates using 3F4 antibody. Data deficient grooming. When held by their tails, some mice
are for mice that are hemizygous for the transgene array. assume an unusual flexed posture, with all four limbs
c Not determined (the founder did not breed and is still alive).
clasped (Figure 1E). As a general rule, Tg(PG14-A2) and
Tg(PG14-A3) mice of both sexes breed poorly, and nurs-
ing mothers often neglect their litters, so their pupsof 14 octapeptide repeats that are rich in proline and
die. To circumvent these problems, we now routinelyglycine. (When this work was previously reported in ab-
maintain the A2 and A3 lines by crossing transgenicstract form [Chiesa et al., 1998], the mutation was re-
males with C57BL/6J 3 CBA/J females or Prn-p0/0 fe-ferred to as PG11, although resequencing of mouse tail
males.DNA reveals that the transgene encodes 14 and not 11
To score the presence of symptoms in mice of differ-octapeptide repeats.) For control purposes, we have
ent ages and genotypes, we evaluated all of the animalsalso produced mice that express a wild-type moPrP
in our colony at a single point in time for the presencetransgene. Both wild-type and PG14 molecules carry an
of four different characteristics (Table 2): (1) foot claspepitope tag for the monoclonal antibody 3F4 (Bolton
reflex, (2) kyphosis, (3) inability to climb on a verticalet al., 1991), which was created by the substitution of
grill for at least 30 sec without falling, and (4) inabilitymethionine residues for leucine 108 and valine 111 (wild-
to balance on a 6 mm Plexiglas ledge for at least 30 sectype numbering). The presence of this epitope, which
without falling. Since even healthy nontransgenic miceis found in human and hamster but not mouse PrP, does
occasionally display one of these characteristics (fornot affect the properties of the protein (Scott et al., 1993)
example, larger mice sometimes have difficulty balanc-and makes it possible to distinguish transgene-encoded
ing on the Plexiglas ledge or climbing on the grill), wePrP from endogenous PrP by using 3F4 antibody.
tabulated the percentage of mice in each age group thatWild-type and PG14 moPrP cDNAs were cloned in
showed two or more of the features (last column of Tablethe transgenic vector MoPrP.Xho, which contains a 12
2). Eighteen of twenty-four Tg(PG14) mice of the A2 andkb fragment of the moPrP gene, including the promoter
A3 lines were ill by this criterion. No mice younger thanand intron 1, and which has been shown to produce
71 days of age were sick, while 73% of mice betweenstrong expression of foreign genes in a tissue pattern
108 and 188 days of age and 100% of mice over 214similar to that of endogenous PrP (Borchelt et al., 1996).
days of age were sick. These results indicate that theInserts excised from the recombinant plasmids were
onset of symptoms is between z100 to 200 days ininjected into the pronuclei of fertilized eggs derived from
Tg(PG14-A2) and Tg(PG14-A3) mice on the C57BL/C57BL/6J 3 CBA/J parental mice, and five transgenic
6J 3 CBA/J background, a conclusion that is confirmedfounder mice for each construct were identified by PCR
screening of tail DNA. Founders were bred back to the by the prospective observation of individual mice. In
contrast, none of the 102 Tg(PG14) mice of the low-parental line, as well as to Prn-p0/0 mice in which the
endogenous PrP gene has been ablated (BuÈ eler et al., expressing B and C lines (the oldest of which is now
532 days of age), and none of the 118 Tg(WT) mice (the1992).
A summary of the transgenic lines is given in Table oldest of which is now 463 days of age), were scored
as ill. Taken together, our results indicate that the over-1. The expression level of transgene-encoded PrP, de-
termined by immunoblot analysis of brain homogenates, expression of wild-type PrP does not produce neurologi-
cal dysfunction and that the development of the diseaseranged from 0.15 to 4.0 times the endogenous level
in the Tg(PG14) mice and from 0.25 to 3.6 times the is related to the expression level of the mutant protein.
We have also observed that the characteristics of theendogenous level in the Tg(WT) mice. The founder with
the highest expression of PG14 PrP (A1) was unable to disease are accentuated by eliminating the expression
of endogenous wild-type PrP. Because of breeding diffi-breed and was sacrificed at 319 days of age after its
neurological symptoms became debilitating. The founder culties, we have been able to recover only a small num-
ber of transgenic mice that are homozygous for thewith the highest number of copies of the wild-type PrP
transgene (D) was also unable to breed but remains disrupted PrP locus, but the chronology of the disease
in these mice is different. Symptoms appeared at z100healthy at 455 days of age.
Transgenic Mice Expressing a Mutant Prion Protein
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Figure 1. Neurological Symptoms in Tg(PG14)
Mice
(A) A Tg(PG14-A3)/Prn-p0/0 mouse at 84 days
of age (left) and a Tg(WT-E1)/Prn-p0/0 mouse
at 89 days of age. Note the ataxic posture of
the PG14 mouse, with the extension of the
hind limbs, the hunchback orientation of the
body, and the ruffled appearance of the coat.
(B) The Tg(PG14-A1) founder at 319 days of
age is completely incapable of ambulating on
a metal grill. Normal mice walk easily on the
grill and rarely let their feet slip through the
bars.
(C) When suspended by its tail, a Tg(WT)
mouse, like a nontransgenic mouse, splays
its hind limbs apart.
(D) In contrast, the Tg(PG14-A3) founder at
324 days of age tightly clasps its hind limbs
together.
(E) At 84 days of age, a Tg(PG14-A3)/Prn-p0/0
mouse suspended by its tail assumes a flexed
posture, attempting to clasp all four limbs
together.
days of age in one Tg(PG14-A2)/Prn-p0/0 and four Tg(PG14) Mice Display Neuropathological Changes
Several abnormalities were observed in the A1, A2, andTg(PG14-A3)/Prn-p0/0 mice that were hemizygous for the
transgene array and at z60 days of age in one Tg(PG14- A3 lines of Tg(PG14) mice. The most obvious pathologi-
cal change was atrophy of the cerebellum, with markedA2)/Prn-p0/0 and two Tg(PG14-A3)/Prn-p0/0 mice that
were homozygous for the transgene array. In addition reduction in the number of granule cells and a decrease
in the thickness of the molecular layer (Figures 2A±2D).to hastening the onset of symptoms, the elimination of
endogenous PrP appeared to shorten the clinical phase These changes were most prominent in Tg(PG14)/Prn-
p0/0 mice but could be observed in a milder form inof the disease. On the C57BL/6J 3 CBA/J background,
the clinical phase is remarkably protracted, with virtually Tg(PG14)/Prn-p1/0 and Tg(PG14)/Prn-p1/1 animals. The
loss of granule cells appeared to become more severeall symptomatic Tg(PG14-A2) and Tg(PG14-A3) mice still
alive, some now 7 months after the onset of symptoms. as the disease progressed. Neuronal loss was not appar-
ent in other areas of the brain, nor was there evidenceIn contrast, of the animals that were homozygous for
the transgene array and that carried the Prn-p0/0 geno- of spongiform degeneration in any region (Figure 3A).
Immunohistochemical staining using anti-GFAP anti-type, the single Tg(PG14-A2) mouse died spontaneously
1.5 months after the illness began, and the two Tg(PG14- body demonstrated gliosis and astrocytic hypertrophy.
These changes were most prominent in the cerebellarA3) mice had to be humanely sacrificed 4 months after
symptom onset. Prior to death, these three animals had cortex, particularly the molecular layer, which displayed
markedly hypertrophied Bergmann glial fibers (Figurebecome severely ataxic and could not walk more than
a few steps without falling. 2E). Increased numbers of enlarged astrocytes were
Table 2. Analysis of Neurological Symptoms in Transgenic Mice
Age Number of Fall from Fall from Number of Mice with
(Days) Mice Testeda Vertical Grill Ledge Foot Clasp Kyphosis at Least Two Symptoms
Tg(PG14-A2)b 28 2 36 9 0 0 0 1 0
and Tg(PG14-A3)b 46 2 71 4 0 1 0 1 0
108 2 188 11 6 3 7 6 8
214 2 368 10 9 9 10 9 10
Tg(PG14-B)c 42 2 45 6 0 0 0 0 0
and Tg(PG14-C)c 99 2 188 45 4 7 0 0 0
195 2 366 51 5 8 1 0 0
Tg(WT)c, all lines 25 2 42 6 0 1 0 0 0
44 2 75 16 0 0 0 0 0
95 2 175 74 5 3 1 0 0
196 2 305 22 4 1 0 1 0
Entries show the number of mice in each category. Data are for the mice on the C57BL/6J 3 CBA/J background.
a One Tg(PG14-B) mouse and one Tg(WT-E1) mouse were excluded from the analysis, because they suffered from an unrelated illness.
b Data are for mice that are hemizygous for the transgene array. (Mice on the C57BL/6J 3 CBA/J background that are homozygous for the
transgene array are not available.)
c Data are for mice that are either hemizygous or homozygous for the transgene array.
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Figure 2. Neuropathological Findings in the Cerebella of Tg(PG14) Mice
(A) Cerebellum of a healthy Tg(WT-E1)/Prn-p0/0 mouse at 184 days of age appears normal after staining with hematoxylin and eosin.
(B) Cerebellar cortex of the same mouse shown in (A), stained with antibody 3F4, shows no deposits of PrP, and the molecular (M), Purkinje
cell (PC), and granule cell (G) layers appear normal.
(C) Cerebellum of a terminally ill Tg(PG14-A3)/Prn-p0/0 mouse at 183 days of age after staining with hematoxylin and eosin. There is marked
atrophy of cerebellum, with reduction in the thickness of the granule cell and molecular layers.
(D) Cerebellar cortex of the same mouse shown in (C), stained with antibody 3F4. There is a dramatic reduction in the density of granule cells
and mild staining for PrP.
(E) Cerebellar cortex of the symptomatic Tg(PG14-A1) founder at 319 days of age, stained for GFAP. There is marked hypertrophy of Bergmann
glial fibers in the molecular layer and increased numbers of astrocytes in the granule cell layer.
(F) Cerebellar cortex of a moderately symptomatic Tg(PG14-A3)/Prn-p0/0 mouse at 71 days of age, stained with antibody 3F4. There is heavy
PrP deposition in a synaptic-like pattern in the molecular layer and less prominent staining in the granule cell layer. Purkinje cells are unstained.
Cerebellar atrophy is less severe in this mouse compared with the older animal shown in (D). Scale bars, 556 mm (A and C), 97 mm (B and
D), 44 mm (E), and 62 mm (F).
also observed in the hippocampus (Figure 3D) and to a campal formation, a strong band of PrP staining was
detected along the perforant pathway, with weakerlesser extent in the neocortex (Figure 3B).
Immunolabeling was performed with anti-PrP anti- staining in the stratum lacunosum-moleculare, radiatum,
and oriens, as well as in the molecular layer of the den-bodies after guanidine thiocyanate treatment and hy-
drolytic autoclaving of sections to enhance reactivity tate gyrus (Figure 3C). In the cerebellum, PrP deposition
was more prominent in the molecular than in the granuleof PrPSc and abolish reactivity of PrPC. Tg(PG14) mice
showed deposits of PrP that were distributed in a fine, cell layers (Figure 2F); Purkinje cells were unstained,
consistent with the fact that the transgenic vector doespunctate pattern that has been described as synaptic-
like (Kitamoto et al., 1992). PrP deposits were most not drive expression in these cells (Fischer et al., 1996).
We observed that PrP staining was less intense in ani-prominent in the cerebellum (Figure 2F), hippocampus
(Figure 3C), and olfactory bulb. The neocortex and mals with a more severe loss of granule cells, suggesting
that granule cells are an important source of these de-inferior colliculus showed a lesser degree of immuno-
labeling. No staining was seen in white matter regions. posits (compare [D] and [F] in Figure 2).
No pathologic changes were observed in Tg(PG14-B),The PrP deposits did not represent amyloid, as judged
by a lack of fluorescence with thioflavin S. In the hippo- Tg(PG14-C), or Tg(WT) mice (Figures 2A and 2B).
Transgenic Mice Expressing a Mutant Prion Protein
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Figure 3. Neuropathological Findings in the Neocortex and Hippocampus of Tg(PG14) Mice
(A) Neocortex of a symptomatic Tg(PG14-A3)/Prn-p1/0 mouse at 175 days of age does not show any spongiform degeneration after staining
with hematoxylin and eosin.
(B) Neocortex of the symptomatic Tg(PG14-A1) founder at 319 days of age shows numerous reactive astrocytes after staining for GFAP.
(C) Hippocampus of the same mouse shown in (A) after staining with 3F4 antibody. There is strong immunolabeling of the perforant pathway
(PF) and less prominent labeling of the molecular layer of the dentate gyrus (asterisk).
(D) Hippocampus of the same mouse shown in (B) displays numerous reactive astrocytes after staining for GFAP. Scale bars, 78 mm (A), 89
mm (B), 109 mm (C), and 141 mm (D).
Detergent-Insoluble PrP Is Present in the Brains protein from Tg(PG14-A1), Tg(PG14-A2), and Tg(PG14-
A3) mice was found in the pellet. In mice from the low-of Tg(PG14) Mice
PrPSc can be recognized by several distinctive biochemi- expressing Tg(PG14-B) and Tg(PG14-C) lines, a lesser
proportion of the mutant protein (10%±20%) was deter-cal properties, including detergent insolubility, protease
resistance, and aberrant behavior after treatment with gent insoluble, suggesting a correlation between ex-
pression level and acquisition of this PrPSc property. Ina phospholipase that normally cleaves the glycolipid
anchor at the C terminus of the protein (Lehmann and all PG14 lines, we noticed that the detergent-insoluble
fraction contained primarily the highest molecular massHarris, 1996a). We have assayed PrP in the brains of
transgenic mice for each of these characteristics. glycoforms of PrP, which have presumably been fully
processed in the endoplasmic reticulum and Golgi. ThisWe determined the amount of PrP that is detergent
insoluble by subjecting Triton-deoxycholate extracts of observation is consistent with other evidence indicating
that the oligosaccharide chains of PrP can modulatebrain to ultracentrifugation under conditions that sedi-
ment PrPSc but leave PrPC in the supernatant. As shown acquisition of PrPSc properties (Petersen et al., 1996;
Lehmann and Harris, 1997), although which glycoformsin Figure 4, PG14 PrP from all lines was partially deter-
gent insoluble. Between 50% and 90% of the mutant are converted to PrPSc appears to depend on the prion
Figure 4. PG14 PrP in the Brains of Trans-
genic Mice Is Detergent Insoluble
Detergent lysates of brain (containing 100 mg
of protein) from transgenic mice and Syrian
hamster were centrifuged at 260,000 3 g for
40 min. Proteins in supernatants (S lanes) and
pellets (P lanes) were then separated by SDS-
PAGE and immunoblotted with antibody 3F4.
One-fourth of each sample (lanes 1±16) or the
whole sample (lanes 17±20) was run on the
gel. Mice were of the following ages and clini-
cal status at the time of sacrifice: E1±E4,
203 days old (all healthy); A1, 319 days old
(severely symptomatic); A2, 71 days old
(healthy); A3, 205 days old (mildly symptom-




strain (Caughey and Raymond, 1991; Collinge et al., exogenous proteases (Harris et al., 1993; Chen et al.,
1996; Parchi et al., 1996). No detergent-insoluble PrP 1995). Cleavage at this ªphysiologicalº site results in a
was detected in the brains of normal hamsters or of fragment that can easily be distinguished from PrP 27±
Tg(WT) mice from any of the four lines examined. 30, based on its smaller size after deglycosylation and
The presence of detergent-insoluble PrP in the B and the fact that it reacts with R340 but not 3F4 or 94±107
C lines demonstrates that this biochemical property can antibodies (Figure 5E, lanes 1, 3, and 5). The fact that
be present prior to the development of clinical symp- PG14 and wild-type PrPs display different cleavage pat-
toms. This phenomenon was also observable in the A2 terns provides strong evidence that the conformations
and A3 lines. For example, the A2 mouse used to prepare of the two proteins are different.
the samples shown in Figure 4 (lanes 13 and 14) was
71 days old and was healthy.
PrP in the Brains of Tg(PG14) Mice Remains Membrane
Mutant PrP in the Brains of Tg(PG14) Mice Is Resistant Associated and Hydrophobic after
to Low Concentrations of Protease Phospholipase Treatment
The digestion of PrPSc with proteinase K cleaves the PrPC can be released from cell membranes by digestion
molecule near residue 89, resulting in a protease-resis- with the bacterial enzyme phosphatidylinositol-specific
tant core fragment of 27±30 kDa (designated PrP 27±30); phospholipase C (PIPLC), which cleaves the C-terminal
under the same condition, PrPC is totally degraded glycosyl-phosphatidylinositol (GPI) anchor (Stahl et al.,
(Oesch et al., 1985). To assess the protease resistance 1987). In contrast, PrPSc remains tightly associated with
of PG14 PrP expressed in the brains of transgenic mice, membranes after PIPLC treatment. Although the molec-
we digested detergent extracts of brain with proteinase ular explanation for this abnormal behavior of PrPSc is
K for 30 min at 378C. We found that PG14 PrP from all not yet certain, it can be observed in scrapie-infected
five lines yielded a PrP 27±30 fragment. The fragment brain tissue (Stahl et al., 1990) and cultured cells (Leh-
from the A1, A2, and A3 lines was observed after diges- mann and Harris, 1996a) and in transfected cells ex-
tion with 2±4 mg/ml of proteinase K (Figure 5B), and the pressing moPrPs with pathogenic mutations (Lehmann
one from the B and C lines was seen after digestion and Harris, 1995). We therefore asked whether the same
with 0.5±1 mg/ml of protease (Figure 5C). In contrast, property was displayed by PG14 PrP molecules ex-
wild-type hamster PrP and moPrP from all four Tg(WT) pressed in the brains of transgenic mice. Suspensions
lines was completely degraded at proteinase K concen- of microsomal membranes were treated with PIPLC,
trations as low as 0.5 mg/ml (Figures 5A and 5C). Figure and the amount of PrP released in the medium was
5D, which plots the pooled results from multiple brains determined by immunoblotting membrane and superna-
of each genotype, clearly demonstrates the quantitative tant fractions obtained after centrifugation. Figure 6A
difference in protease resistance between wild-type and shows that while z50% of the wild-type PrP from ham-
mutant PrPs. The lower protease resistance of the PG14 sters and Tg(WT-E1) mice was releasable by PIPLC,
protein from the B and C lines correlates with its lower none of the PG14 PrP from A1, A2, or A3 mice was
detergent insolubility and demonstrates again that ex- releasable. Incomplete release of wild-type PrP is proba-
pression level modulates the acquisition of PrPSc prop-
bly due to its localization within membrane vesicles that
erties. Although PG14 PrP of all lines is more pro-
are inaccessible to the phospholipase; this explanation
tease-resistant than wild-type PrP, the mutant protein
is consistent with the slightly faster electrophoretic mo-is significantly less protease-resistant than PrPSc from
bility of the nonreleased molecules, which indicates thatscrapie-infected brain. For example, using conditions
their GPI anchors have not been cleaved (Rosenberry,identical to those employed to digest PG14 PrP, we find
1991).that PrP from hamster brain infected with the 263K strain
After cleavage of its GPI anchor by PIPLC, PrPC isof scrapie can withstand treatment with as much as 100
converted from a hydrophobic to a hydrophilic molecule,mg/ml of proteinase K (data not shown).
a change that can be registered by observing a shift inMapping of the immunoreactive epitopes present in
the distribution of the protein from the detergent to thePrP 27±30 from Tg(PG14) mice suggests that this frag-
aqueous phase following partitioning in Triton X-114ment is produced by cleavage in the same region where
(Englund, 1993). We have observed that mutant PrPauthentic PrPSc is cut. The fragment reacts with mono-
molecules expressed in cultured cells are partially re-clonal antibody 3F4, the epitope for which encompasses
tained in the detergent phase even after PIPLC treat-residues 108±111; with a polyclonal antibody (Piccardo
ment, a phenomenon that reflects an early step in theet al., 1998) directed against moPrP residues 94±107;
conversion of the protein to the PrPSc state (Lehmannand with R340 (Shmerling et al., 1998), a polyclonal anti-
and Harris, 1995; Daude et al., 1997). We tested whetherbody that reacts with epitopes C-terminal to position
this property was also exhibited by PG14 PrP expressed121 (Figure 5E, lanes 2, 4, and 6). It does not react with
in transgenic mouse brain. Figure 6B shows that beforea polyclonal antibody (Lehmann and Harris, 1995) that
treatment with PIPLC, both wild-type and PG14 PrPsrecognizes moPrP residues 45±66 (data not shown).
partitioned almost exclusively into the detergent phase,These results indicate that proteinase K truncates the
as would be expected for molecules carrying an intactN terminus of PG14 PrP between the end of the octapep-
GPI anchor. After PIPLC treatment, about 40% of wild-tide repeats and amino acid 94, the same region where
type PrP from hamsters and Tg(WT-E1) mice was shiftedauthentic PrPSc is cleaved. This site is distinct from one
into the aqueous phase. In contrast, PG14 PrP from thewithin the central hydrophobic domain (residues 110±
A1, A2, and A3 lines remained in the detergent phase.120) that is particularly protease-sensitive in the wild-
type protein and that is cleaved by cellular as well as The incomplete shift of wild-type PrP into the aqueous
Transgenic Mice Expressing a Mutant Prion Protein
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Figure 5. PG14 PrP in the Brains of Transgenic Mice Is Protease Resistant
(A±C) Detergent lysates of brains from transgenic mice and Syrian hamster were incubated with the indicated amounts of proteinase K (PK)
for 30 min at 378C. Digestion was terminated by the addition of PMSF, and methanol-precipitated proteins were separated by SDS-PAGE and
immunoblotted with antibody 3F4. Two hundred micrograms (A and B) or 800 mg (C) of initial protein was subjected to digestion. The lanes
containing undigested samples (0 mg/ml PK) represent 50 mg (A and B) or 200 mg (C) of protein. Age and clinical status of mice at the time
of sacrifice are given in the legend to Figure 4.
(D) The amount of PrP remaining after digestion with the indicated concentrations of proteinase K was quantitated by densitometric analysis
of Western blots such as those shown in (A) through (C) and expressed as a percentage of the initial amount. Each point represents the
mean 6 SD of 19 replicates from 11 brains (closed circles), 19 replicates from 8 brains (closed squares), and 7 replicates from 3 brains (closed
triangles).
(E) Samples from Tg(WT-E1)/Prn-p0/0 and Tg(PG14-A3)/Prn-p0/0 brains were digested with 3 mg/ml proteinase K, deglycosylated with
N-glycosidase F, and subjected to immunoblotting with the indicated antibodies. The arrowhead indicates a PrP 27±30 fragment generated
only from the mutant protein (lanes 2, 4, and 6), and the arrow indicates a shorter fragment that is produced from both proteins as a result
of cleavage at a slightly more C-terminal site (lanes 1 and 2).
phase is probably due to incomplete solubilization of 4-day-old mice, PG14 PrP is already more detergent
insoluble and protease resistant than wild-type PrP (Fig-the protein (unpublished data).
ure 7).
PG14 PrP Is Detergent Insoluble and Protease
Resistant in Very Young Mice
As a first step in determining when during development Discussion
PG14 PrP is converted to a PrPSc-like state, we have
carried out biochemical assays of the mutant protein We have produced a neurological disorder in mice by
the introduction of a transgene that encodes the moPrPfrom the brains of neonatal animals. We find that in
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Figure 6. PG14 PrP in the Brains of Trans-
genic Mice Is Not Released from Membranes
and Remains Hydrophobic after Treatment
with PIPLC
(A) Suspensions of brain membranes from
transgenic mice and Syrian hamster were in-
cubated with PIPLC for 2 hr at 48C, and mem-
branes were collected by centrifugation. PrP
in the supernatant (S) and membrane (M) frac-
tions was then visualized by immunoblotting
with 3F4 antibody. (B) Brain homogenates
were solubilized in a buffer containing 1%
Triton X-114 at 48C, and then phase separa-
tion was induced by raising the temperature
to 378C. The detergent phase was recovered
and diluted to the original volume. One half
was incubated with PIPLC at 48C for 2 hr
(1 lanes), and the other half was left untreated
(2 lanes). Phase separation was repeated,
and PrP in the detergent (D lanes) and aque-
ous (A lanes) phases was analyzed by immu-
noblotting with 3F4 antibody. Age and clinical
status of mice at the time of sacrifice are
given in the legend to Figure 4.
homolog of a nine octapeptide insertional mutant asso- age) and histologically normal (260 days of age), al-
though PrPSc-like forms are detectable biochemically inciated with an inherited prion dementia in humans.
their brains (see below). Whether the low-expressingThese mice develop progressive neurological symp-
Tg(PG14) mice will eventually become ill remains to betoms, display pathological changes in their brains, and
determined. A similar effect has been observed in P101Lsynthesize mutant PrP that displays four different bio-
mice, in which overexpression of the mutant transgenechemical properties reminiscent of PrPSc. Since we ob-
by 8- or 32-fold produced a GSS-like illness, while 2-foldserve these features in three independent transgenic
overexpression did not (Hsiao et al., 1990; Telling et al.,lines bred on two different genetic backgrounds, the
1996). Presumably, at higher expression levels, morephenotype is almost certainly due to expression of the
mutant PrP molecules are converted to the PrPSc state,PG14 transgene rather than to disruption of an endoge-
with earlier development of disease. At expression levelsnous locus or to other genetic factors. Moreover, since
that are sufficiently low, symptoms may not appear dur-the disease is seen in mice that express the mutant
ing the lifetime of the animal.PrP at levels equivalent to that of endogenous PrP, the
We have also found that coexpressed wild-type PrPsymptoms are not attributable to massive overexpres-
appears to modify the disease phenotype in Tg(PG14)sion of the transgene. Finally, we do not observe any
mice. Although we have thus far observed only a smallabnormalities in five lines of mice that express a wild-
number of animals, we find that the elimination of endog-type PrP transgene over a wide range of expression
enous PrP by crossing onto the Prn-p0/0 genotype short-levels, making it very likely that the phenotype results
ens the onset of disease in the A2 and A3 lines fromspecifically from the presence of the octapeptide inser-
100±200 days to z100 days in mice that are hemizygous
tion in the PrP molecule.
for the transgene array, with a further reduction to z60
days when the transgene array is bred to homozygosity.
Expression Level and Endogenous PrP Removal of endogenous PrP also accelerates the symp-
Modify the Phenotype tomatic phase of the disease. Since Prn-p0/0 mice were
We have observed that the expression level of the mu- constructed on a 129 3 C57BL/6J background, while
tant transgene dramatically affects development of the the parental mice were CBA/J 3 C57BL/6J F1 hybrids,
disease in Tg(PG14) mice. Mice in which PG14 PrP is our conclusions are subject to the caveat that unlinked
expressed at the same level as endogenous PrP devel- genetic loci rather than the absence of PrP could be
oped neurological symptoms and displayed PrP depos- responsible for accentuation of the phenotype in Prn-
its in their brains at 100±200 days of age. In contrast, p0/0 animals. Similar to our results, the absence of endog-
mice expressing the mutant protein at 15% of the en- enous wild-type PrP in P101L mice decreased and syn-
chronized the age of onset of the disease, shorteneddogenous level remain clinically normal (532 days of
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PrP in Tg mice has recently been reported to result
in the selective destruction of cerebellar granule cells
(Shmerling et al., 1998). This raises the possibility that
granule cells are particularly dependent on a specific
physiological function of PrPC and that either insertions
or deletions in the N terminus of the protein disrupt this
function. A line of Prn-p0/0 mice (different from the one
used here, which is histologically normal (Shmerling et
al., 1998)) showed ataxia and cerebellar atrophy, but
these animals differ from Tg(PG14) mice, because they
display a selective loss of Purkinje cells, with a sparing
of granule cells (Sakaguchi et al., 1996).
Mutant PrP in the Brains of Tg(PG14) Mice
Has Properties Reminiscent of PrPSc
Many lines of evidence point to the central role of PrPSc
in the etiology and pathogenesis of prion diseases, and
this isoform is present in almost all infectious, sporadic,
and familial cases (Prusiner et al., 1998). We have found
that mutant PrP in the brains of Tg(PG14) mice displays
four biochemical properties that are reminiscent of
PrPSc, including detergent insolubility, production of a
PrP 27±30 core fragment upon proteinase K digestion,
lack of release from membranes by PIPLC, and hydro-
phobicity after PIPLC treatment. We have observed the
same four properties in mutant PrP molecules, includingFigure 7. PG14 PrP Is Detergent Insoluble and Protease Resistant
in the Brains of Neonatal Mice those carrying insertional mutations, that are synthe-
Detergent insolubility (A) and protease resistance (B) were deter- sized in transfected lines of CHO cells (Lehmann and
mined as described in the legends to Figures 4 and 5. Mice were 4 Harris, 1995, 1996a, 1996b), and others have now re-
days old. ported similar results in other cell lines (Singh et al.,
1997; Priola and Chesebro, 1998).
Mutant PrP in the brains of Tg(PG14) mice differs fromthe duration of the clinical phase, and accentuated the
neuropathological findings (Telling et al., 1996). One hy- authentic PrPSc primarily in its lower level of protease
resistance. Although PrPSc from patients with the ninepothesis to explain the inhibitory effect of wild-type PrP
is competition for hypothetical cellular factors that are octapeptide insertion has not been characterized, PrPSc
found in humans with other familial prion diseases andrequired for PrPSc formation.
in scrapie-infected rodents can typically withstand treat-
ment with 20±100 mg/ml of proteinase K for 0.5±2 hrCerebellar Pathology in Tg(PG14) Mice
Although PrP deposits and gliosis are observed in sev- (Scott et al., 1993; Fischer et al., 1996; Capellari et al.,
1997; Chen et al., 1997). The concentration of proteaseeral regions of the brain, atrophy of the cerebellum, with
the depletion of granule cells, is a consistent feature of we have used to digest PrP from the transgenic mice
is 10±100 times lower. This difference may imply thatthe neuropathological phenotype of Tg(PG14) mice. We
also observed thinning of the molecular layer, but this the protein from Tg(PG14) mice has been only partially
converted to the PrPSc state, as has been suggested formay be due in part to the loss of parallel fibers from the
diminished number of granule cells. Further work will wild-type PrP in the brains of heterozygous patients
carrying the E200K PrP mutation (Gabizon et al., 1996).be needed to determine the precise time course of gran-
ule cell loss, but our preliminary results indicate that the Alternatively, mutant PrP in Tg(PG14) mice may be au-
thentic PrPSc, but its level of protease resistance maycells are initially present in normal numbers and then
degenerate, rather than failing to develop in the first be lower because of the shorter duration of the illness
in Tg(PG14) mice compared with humans with inheritedplace. There was not a marked reduction in the density
of Purkinje cells in Tg(PG14) mice, but additional analy- prion diseases or because of differences in the way that
mouse cells metabolize or process the mutant protein.sis will be necessary to determine if there is any effect
on this cell type. In fact, the protease resistance of PrPSc can vary consid-
erably depending on the prion strain from which it isCerebellar pathology has been observed in humans as
well as in other mice with PrP-related diseases. Marked derived (Bessen and Marsh, 1992). Clearly, the definitive
test will be to determine whether PG14 PrP from theatrophy of the cerebellum, including both the molecular
and granule cell layers, was observed in one patient from transgenic mice is infectious after inoculation into other
mice, an experiment which is currently underway. Evena large British kindred with a six octapeptide insertion
(Collinge et al., 1992), and granule cell depletion has if the mutant protein should not turn out to be infectious,
however, the fact that it possesses other PrPSc-like prop-been described in a number of cases of familial and
sporadic CJD (Parchi et al., 1998). It is of interest that erties, in addition to protease resistance, and the fact
that it is associated with a neurological illness make itthe expression of two N-terminally truncated forms of
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likely that at least some aspects of PrPSc formation are formation between different types of neurons that may
be critical in determining the phenotype of familial prionbeing modeled in Tg(PG14) mice.
We have detected PrP with scrapie-like properties in diseases. Finally, Tg(PG14) mice with low expression
levels of the mutant protein will be useful hosts for test-the brains of Tg(PG14) mice within the first week of life,
well before the animals develop clinical symptoms or ing the infectivity of PG14 molecules that are generated
in transgenic lines with higher expression levels and inneuropathological changes. If the same is true in human
patients, then mutant PrP may be converted to the cell culture and in vitro systems.
scrapie form throughout life but only accumulate to toxic
Experimental Procedureslevels after many years. This may explain why individuals
carrying PrP mutations do not manifest symptoms of
Production of Transgenic Micethe disease until adulthood, even though the mutant
We have previously described the construction of cDNAs encoding
protein is presumably synthesized from before birth wild-type and PG14 moPrPs that are derived from the Prn-pa allele
(Manson et al., 1992). It is also possible that the mutant and contain a 3F4 epitope tag (Lehmann and Harris, 1995). The
PG14 cDNA was originally designated PG11, although resequencingprotein changes in a qualitative way over time to become
now reveals that it encodes 14 and not 11 octapeptide repeats (S.more ªPrPSc-like.º Thus, we observed that the PG14 pro-
Lehmann and D. H., unpublished data). The coding regions of thesetein in the A1, A2, and A3 lines is more detergent insolu-
cDNAs were amplified by PCR using Vent polymerase (New Englandble and is resistant to higher concentrations of protein-
Biolabs) with sense (GACCAGCTCGAGATGGCGAACCTTGGCTAC
ase K than the protein from the B and C lines that have TGG) and antisense (GACCAGCTCGAGTCATCCCACGATCAGGAA
yet to become ill. It is possible that the detergent insolu- GAT) primers containing XhoI sites. PCR products were digested
with XhoI and ligated into the expression vector MoPrP.Xho (Bor-bility and protease resistance of the PrP in the B and C
chelt et al., 1996), which had also been cut with XhoI. Recombinantlines will increase as the animals age further, and this
plasmids with inserts in the correct orientation were selected bymight correlate with the eventual development of clinical
PCR screening of bacterial colonies using primers P3 and P4 (seesymptoms.
below), and their identity was confirmed by restriction analysis and
sequencing of the coding regions in their entirety. Transgenes were
excised from the recombinant plasmids by digestion with NotI, puri-
Tg(PG14) Mice Are Different from Other fied on NACS-52 Prepac columns (Gibco BRL), and injected into
the pronuclei of fertilized eggs from an F2 cross of C57BL/6J 3Transgenic Models
CBA/J F1 parental mice. Transgenic founders were bred to C57BL/Several different kinds of PrP transgenic mice have been
6J 3 CBA/J F1 parental mice or to Prn-p0/0 mice obtained fromdescribed that spontaneously develop a neurological
Charles Weissmann that were produced on a 129 3 C57BL/6J back-illness (Westaway et al., 1994; Muramoto et al., 1997;
ground (BuÈ eler et al., 1992).
Hegde et al., 1998; Shmerling et al., 1998). The only The PrP gene status of weanling mice was determined by PCR
others that express a mutant PrP associated with a analysis of tail DNA prepared with a Puregene DNA Isolation Kit
from Gentra Systems. Primers P1 and P4 were used to detect thehuman familial prion disease are the P101L mice studied
presence of the transgene, since they amplify an 842 bp segmentby Prusiner and colleagues that carry the mouse homo-
of the wild-type transgene and a 1058 bp segment of the PG14log of a GSS-related P102L mutation (Hsiao et al., 1990;
transgene, but they do not amplify the Prn-p or Prn-p0 genes. PrimerTelling et al., 1996). High-expressing lines of these mice
pairs P2/P4 and P3/P4 were used to follow segregation of the Prn-p
spontaneously developed neurological symptoms and and Prn-p0 genes. P2 and P4 amplify an 859 bp segment of the
displayed spongiform degeneration, astrocytic gliosis, Prn-p gene and a 1.4 kb segment of the Prn-p0 gene, but no product
is formed from either transgene. P3 and P4 amplify a 658 bp segmentand PrP-containing plaques in their brains, as well as a
of both the Prn-p gene and the wild-type transgene and an 874 bpperipheral neuromyopathy not commonly seen in human
segment of the PG14 transgene, but no product is formed from theGSS. Brain homogenates from spontaneously ill mice
Prn-p0 gene. PCR was performed at 948C (30 sec), 508C (30 sec),could serially transmit the disease to low-expressing
and 728C (45 sec) for 40 cycles. Primer sequences were AACCGAGC
P101L mice (which did not become ill in the absence of TGAAGCATT (P1); CTTCAGCCTAAATACTGG (P2); AGCCCTGGAG
inoculation) and to 10% of hamsters but not to non- GCAACCG (P3); and CACGAGAATGCGAAGG (P4).
Southern blot analysis was performed using the Gene Imagestransgenic mice (Hsiao et al., 1994). Mutant PrP from
CDP-Star Chemiluminescent Detection System (Amersham). A 485these mice was not resistant to digestion with concen-
bp KpnI segment from the 39 end of the moPrP coding region wastrations of proteinase K as low as 10 mg/ml for 1 hr and
used as a probe to detect the following fragments in EcoRI-digestedwas not more detergent insoluble than wild-type PrP
tail DNA: a 3.2 or 3.4 kb fragment derived, respectively, from the
(Telling et al., 1996). It is possible that protease-resistant wild-type or PG14 transgene; a 2.5 kb fragment derived from the
PrP would have been detected in these mice by using Prn-p gene; or a 1.5 kb fragment from the Prn-p0 gene. The relative
intensity of the 3.2 or 3.4 kb bands compared with the intensity ofthe slightly milder conditions we have employed here.
the 2.5 or 1.5 kb bands was used to estimate the transgene copyAlternatively, the PG14 mutation may favor the acquisi-
number and to discriminate between the hemizygous and homozy-tion of PrPSc-like properties more than the P101L mu-
gous states of the transgene array.tation.
Tg(PG14) mice will be extremely valuable for a number Clinical Analysis of Mice
of studies. First, they will allow analysis of the complete Mice were housed in a barrier facility in which no scrapie agent
had ever been used. Mice were observed weekly for symptoms ofclinical and neuropathological course of an inherited
neurological dysfunction. It was easy to identify symptomatic miceprion disease in an animal model and testing of the
by observation of their appearance, their spontaneous movements,effects of therapeutic agents. Second, they will make it
and their response to being held by their tails. To objectively scorepossible to analyze the conversion of a mutant PrP to
the presence of symptoms (Table 2), all of the mice in the colony
a PrPSc-like state in differentiated neurons, whereas pre- were evaluated at a single point in time for the presence of four
viously this has only been feasible in transformed cell characteristics. First, foot clasp reflex was evaluated by suspending
mice by the tail for 30 sec and observing if they clasped their hindlines in culture, and to investigate variations in PrPSc
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limbs together; normal mice splay their limbs apart. Second, kypho- centrifuged at 16,000 3 g for 5 min at 48C to prepare microsomal
membranes. Membranes were resuspended in PBS containing pro-sis was assessed by visual inspection. Third, mice were placed head
downward in the center of a vertically oriented grill (45 3 45 cm) tease inhibitors, incubated at 48C with 1 unit/ml of PIPLC from Bacil-
lus thuringiensis as described previously (Harris et al., 1993), andconsisting of steel rods (3 mm diameter) with a center-to-center
spacing of 7 mm (this apparatus is shown in the horizontal orienta- then centrifuged at 16,000 3 g for 5 min. PrP in the supernatant
and pellets was analyzed by Western blotting.tion in Figure 1B). Normal mice easily turn around and begin climbing
toward the top of the grill, while mice that are ill fall off when they To assay hydrophobicity, postnuclear supernatants were diluted
into ice-cold 1% Triton X-114 in PBS containing protease inhibitors,try to maneuver. If an animal could not remain on the apparatus for
at least 30 sec without falling, it was scored as positive. Fourth, and phase separation was carried out as described previously
(Daude et al., 1997). Proteins in the detergent and aqueous phasesmice were allowed to walk on a narrow (6 mm wide) Plexiglas ledge.
If they could not maintain their balance on the ledge for at least 30 were methanol precipitated, and PrP was visualized by Western
blotting.sec without falling, they were scored as positive. Padding was
placed under both the grill and the ledge to prevent injury from
falling. The third and fourth tests are modifications of sensorimotor Acknowledgments
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